Unknown

Dataset Information

0

Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.


ABSTRACT: PURPOSE:Plasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females. METHODS:Between 1 July 2014 and 31 December 2015, we screened 2,359 patients (1,324 males) referred from 168 Japanese specialty clinics (cardiology, nephrology, neurology, and pediatrics), based on clinical symptoms suggestive of Fabry disease. We used the plasma lyso-Gb3 concentration, ?-galactosidase A (?-Gal A) activity, and analysis of the ?-Gal A gene (GLA) for primary and secondary screens, respectively. RESULTS:Of 8 males with elevated lyso-Gb3 levels (?2.0?ng?ml-1) and low ?-Gal A activity (?4.0?nmol?h-1?ml-1), 7 presented a GLA mutation (2 classic and 5 late-onset). Of 14 females with elevated lyso-Gb3, 7 displayed low ?-Gal A activity (5 with GLA mutations; 4 classic and 1 late-onset) and 7 exhibited normal ?-Gal A activity (1 with a classic GLA mutation and 3 with genetic variants of uncertain significance). CONCLUSION:Plasma lyso-Gb3 is a potential primary screening biomarker for classic and late-onset Fabry disease probands.

SUBMITTER: Maruyama H 

PROVIDER: S-EPMC6363642 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.

Maruyama Hiroki H   Miyata Kaori K   Mikame Mariko M   Taguchi Atsumi A   Guili Chu C   Shimura Masaru M   Murayama Kei K   Inoue Takeshi T   Yamamoto Saori S   Sugimura Koichiro K   Tamita Koichi K   Kawasaki Toshihiro T   Kajihara Jun J   Onishi Akifumi A   Sugiyama Hitoshi H   Sakai Teiko T   Murata Ichijiro I   Oda Takamasa T   Toyoda Shigeru S   Hanawa Kenichiro K   Fujimura Takeo T   Ura Shigehisa S   Matsumura Mimiko M   Takano Hideki H   Yamashita Satoshi S   Matsukura Gaku G   Tazawa Ryushi R   Shiga Tsuyoshi T   Ebato Mio M   Satoh Hiroshi H   Ishii Satoshi S  

Genetics in medicine : official journal of the American College of Medical Genetics 20180315 1


<h4>Purpose</h4>Plasma globotriaosylsphingosine (lyso-Gb3) is a promising secondary screening biomarker for Fabry disease. Here, we examined its applicability as a primary screening biomarker for classic and late-onset Fabry disease in males and females.<h4>Methods</h4>Between 1 July 2014 and 31 December 2015, we screened 2,359 patients (1,324 males) referred from 168 Japanese specialty clinics (cardiology, nephrology, neurology, and pediatrics), based on clinical symptoms suggestive of Fabry di  ...[more]

Similar Datasets

| S-EPMC7609257 | biostudies-literature
| S-EPMC3589404 | biostudies-literature
| S-EPMC4428877 | biostudies-literature
| S-EPMC6239936 | biostudies-literature
| S-EPMC6336544 | biostudies-literature
| S-EPMC7696179 | biostudies-literature
| S-EPMC4411215 | biostudies-literature
| S-EPMC7790748 | biostudies-literature
| S-EPMC4992964 | biostudies-literature
| S-EPMC10478213 | biostudies-literature